Nitric oxide-donating compounds for IOP lowering in glaucoma.

CONCLUSIONS: The mechanism of action of these compounds is novel and scientific evidence that shows promising results. However, there is a need for more comprehensive studies to assess long-term safety and tolerability in order to properly evaluate their use in chronic therapies.
PMID: 29580758 [PubMed - as supplied by publisher]

Source: Archivos de la Sociedad Espanola de Oftalmologia - March 29, 2018 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research